Company Overview of XORTX Pharma Corp.
XORTX Pharma Corp., a drug development company, develops cardio-vascular medications. The company offers its products for the treatment of rare diseases, such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, and cystic fibrosis, as well as other diseases, including hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. It develops oxypurinol, a uric acid lowering agent; and xanthine oxidase inhibitor for the treatment of orphan and other common diseases. The company was incorporated in 2012 and is based in Calgary, Canada.
4000, 421 7th Ave SW
Calgary, AB T2P 4K9
Founded in 2012
Key Executives for XORTX Pharma Corp.
Similar Private Companies By Industry
|1127466 B.C. Ltd.||Americas|
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
Recent Private Companies Transactions
June 14, 2017
June 14, 2017
|APAC Resources Inc.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact XORTX Pharma Corp., please visit www.xortx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.